Arcturus Therapeutics Holdings Inc.
HealthcareNASDAQ:ARCT · NASDAQ Global Market
+$0.00 today
Vol 0.29M · Avg 0.45M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-30.7%
avg -50.2%
ROIC
-31.4%
avg -34.8%
ROA
-24.3%
avg -26.9%
Analysis
ROA is currently the strongest return metric at -24.3% versus its period average of -26.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Joseph E. Payne | Founder, President, Chief Executive Officer & Director | $750,000.00 | — | 54 | $10,000.00 | 0.04% |
Padmanabh Chivukula | Founder, Chief Scientific Officer, Chief Operating Officer & Secretary | $572,000.00 | — | 47 | $54,000.00 | 0.19% |
Lance Kurata | Chief Legal Officer | $540,000.00 | — | — | $54,000.00 | 0.19% |
Joseph Roberts | Principal Accounting Officer & Controller | $219,580.00 | — | 43 | $10,000.00 | 0.04% |
Alan H. Cohen FAAAAI FAAP FACAAI FCCP | Chief Medical Officer | — | — | 65 | — | — |
Ye Zhang | Chief Regulatory & Quality Assurance Officer | — | — | — | — | — |
Kevin T. Skol | Chief Business Officer | — | — | — | — | — |
Dennis Mulroy | Chief Financial Officer | — | — | 71 | $100,000.00 | 0.35% |
Igor Smolenov | Chief Development Officer | — | — | — | — | — |
Natash O. Bowman | Chief Human Resources Officer | — | — | — | — | — |
Neda Safarzadeh | Vice President and Head of IR/PR & Marketing | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$20,498.80
Sells
1
$20,498.80
Net Sentiment
+$0.00
Net buying
Most Active
SASSINE ANDY
2 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Aug 15, 2025 | SASSINE ANDY Direct | Buy | 1.2K | $16.56 | $20,498.80 | |
| Aug 15, 2025 | SASSINE ANDY Direct | Sell | 1.2K | $16.56 | $20,498.80 |
Analysis
Insiders reported 1 buys worth $20,498.80 and 1 sells worth $20,498.80 over the last 12 months. That adds up to net buying of $0.00. SASSINE ANDY was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | +26.5% (15yr)7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Forward estimates point to Revenue at +26.5% (15yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Achieve Life Sciences, Inc.
NASDAQ:ACHV
$566.68M
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$359.32M
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
$353.00M
Entrada Therapeutics, Inc.
NASDAQ:TRDA
$250.78M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$245.42M
Zura Bio Limited
NASDAQ:ZURA
$240.58M
Voyager Therapeutics, Inc.
NASDAQ:VYGR
$211.47M
Sagimet Biosciences Inc.
NASDAQ:SGMT
$211.13M
Humacyte, Inc.
NASDAQ:HUMA
$177.24M
Immuneering Corporation
NASDAQ:IMRX
$152.11M
Who manages ARCT?
Arcturus Therapeutics Holdings Inc. (ARCT) lists 11 active executives. The top listed executive is Alan H. Cohen FAAAAI FAAP FACAAI FCCP, Chief Medical Officer.
Are ARCT insiders buying or selling?
Recent insider activity shows net selling of $32.07M.
Explore More
Continue the stock analysis
Jump to another research area for this company.